The purpose of the report is to illustrate the state of the market of Asthma And COPD Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report: https://www.credenceresearch.com/report/asthma-and-copd-drugs-market
Globally, asthma and COPD is one the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. Thus, disease represent a lucrative market for pharmaceutical companies. COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risk such as smoking, pollution is not addressed. Gradually over the period of time the treatment of asthma and COPD shows improvement, with novel drugs and treatment strategies, along with usage of non-pharmacologic treatment. It has being observed there is being surge in prevalence of asthma and COPD in developed and developing countries. In developed countries, there is being rise in prevalence of asthma due to lifestyle changes in terms of food habit, low level of exercise, etc., while in developing countries the prevalence is due to pollution and smoking.
The global asthma and COPD drugs market is segmented by drug type into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergic drugs. Amongst all, combination therapy of long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) dominates the market. The combination therapy that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline) is most preferred treatment against asthma/ COPD, due to better efficacy and less side effects.
As of the current market scenario, North America together dominate the global asthma and COPD drugs market followed by the European market. Rising prevalence of asthma and COPD due to pollution, change in lifestyle, entry of generics and novel therapies in the market. Asia Pacific is anticipated to be the fastest growing market for the forecast period. Emerging economies such India, China due to industrialization, demographic changes, urbanization there is been rise in pollution thus increase in prevalence of asthma and COPD population.
Market Competition Assessment:
Key players in the global asthma and COPD drugs market are Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer Inc. and others.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Asthma And COPD Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Asthma And COPD Drugs contains:
Analysis and forecast of Asthma And COPD Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Asthma And COPD Drugs market;
Assessment and forecast of Asthma And COPD Drugs market development;
Financial and business profiles of the leading companies in the Asthma And COPD Drugs industry.
– Up to date working Asthma And COPD Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Asthma And COPD Drugs for the period 2018 to 2026
– Planned Asthma And COPD Drugs additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Asthma And COPD Drugs projects by region, key countries, and companies
– Details of major planned Asthma And COPD Drugs projects in the world up to 2026
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58486
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290